JAGUAR HEALTH, INC. Unamortized Debt Issuance Expense
JAGUAR HEALTH, INC. (JAGX) had Unamortized Debt Issuance Expense of $250.02 thousand as of 2015-12-31, per its 10-K filed 2016-03-29.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:UnamortizedDebtIssuanceExpense · last filed 2016-03-29
- 2015-12-31: Unamortized Debt Issuance Expense $250.02K.
- 2014-12-31: Unamortized Debt Issuance Expense $104.00K.
| Period end | Unamortized Debt Issuance Expense |
|---|---|
| 2015-12-31 | $250.02K 10-K · filed 2016-03-29 |
| 2014-12-31 | $104.00K 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |